Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$0.69
-0.6%
$0.69
$0.45
$1.99
$52.38M1.43406,966 shs66,632 shs
89BIO stock logo
ETNB
89BIO
$10.14
+0.4%
$9.26
$4.16
$11.84
$1.48B1.281.52 million shs1.94 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.55
$4.82
$19.50
$97.22M-0.8862,718 shsN/A
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$11.83
$11.83
$3.21
$18.22
$621.21M1.781.52 million shs1,084 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.03
+2.0%
$0.03
$0.02
$6.93
$673K1.318.06 million shs44,922 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
0.00%-7.15%+10.97%+1.91%-29.80%
89BIO stock logo
ETNB
89BIO
0.00%+2.84%+0.80%+75.74%+35.56%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%+5.49%-39.05%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%-16.05%0.00%+5.46%-99.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
4.1057 of 5 stars
3.52.00.04.72.60.80.6
89BIO stock logo
ETNB
89BIO
1.9346 of 5 stars
3.51.00.00.02.30.80.6
OptiNose, Inc. stock logo
OPTN
OptiNose
0.7423 of 5 stars
1.00.00.04.20.61.70.6
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.3572 of 5 stars
3.15.00.04.31.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.00
Buy$3.00336.05% Upside
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43160.64% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3313,180.21% Upside

Current Analyst Ratings Breakdown

Latest STML, CUE, OPTN, ETNB, and SYRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/19/2025
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.00
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/8/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$9.29M5.58N/AN/A$0.28 per share2.46
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$43.22M14.37N/AN/A$3.26 per share3.63
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K1.74N/AN/A$0.79 per share0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)

Latest STML, CUE, OPTN, ETNB, and SYRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million
5/12/2025Q1 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.03
1.03
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/A
7.43
7.37
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
89BIO stock logo
ETNB
89BIO
N/A
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
75.80%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
10.78%
89BIO stock logo
ETNB
89BIO
2.60%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
11.20%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
6075.35 million67.23 millionOptionable
89BIO stock logo
ETNB
89BIO
40145.98 million142.19 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
9252.51 millionN/AOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable

Recent News About These Companies

Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
SYRS’s Latest Surge: What’s Behind the Spike?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$0.69 0.00 (-0.58%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$0.69 +0.00 (+0.58%)
As of 07/3/2025 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$10.14 -0.01 (-0.05%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

OptiNose stock logo

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)
As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Stemline Therapeutics stock logo

Stemline Therapeutics NASDAQ:STML

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.03 +0.00 (+2.03%)
As of 07/3/2025 12:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.